Our efforts to develop antibodies for pancreatic cancer markers have been featured as a “Success Story” on iBody Inc.’s website.

Our CEO, Taniuchi, discusses the importance of acquiring high-quality antibodies for realizing next-generation pancreatic cancer diagnosis and treatment, along with our future business outlook. We encourage you to read about this case study, which combines iBody’s innovative single-cell technology with our research achievements.

Click here to view published documents. (Japanese language)

Click here to view iBody Inc.’s website.